Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Talipexole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 8/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 8/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.97 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.97 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.97 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.35 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.34 |
| ▸ | HRH2 known ✓ | P25021 | 2/20 | 0.33 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.33 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.33 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.33 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.33 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.33 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Talipexole SCHEMBL18203528 | 1.00 | MAPT (1.00) | MAPTRAD52KDM4EALDH1A1DRD2 | |
| Talipexole SCHEMBL385161 | 1.00 | MAPT (1.00) | MAPTRAD52KDM4EALDH1A1DRD2 | |
| Talipexole SCHEMBL5605621 | 0.98 | DRD2 (1.00) | MAPTRAD52KDM4EALDH1A1DRD2 | |
| Talipexole SCHEMBL49817 | 0.98 | DRD2 (1.00) | MAPTRAD52KDM4EALDH1A1DRD2 | |
| Talipexole SCHEMBL678761 | 0.95 | DRD2 (0.94) | MAPTRAD52KDM4EALDH1A1DRD2 | |
| Hydrochloric Acid SCHEMBL10652670 | 0.80 | RAD52 (0.77) | MAPTRAD52KDM4EALDH1A1DRD2 | |
| SCHEMBL563307 | 0.78 | RAD52 (0.79) | MAPTRAD52KDM4EALDH1A1DRD2 | |
| Hydrochloric Acid SCHEMBL11395621 | 0.77 | MAPT (0.62) | MAPTRAD52KDM4EALDH1A1DRD2 | |
| Hydrochloric Acid SCHEMBL10657526 | 0.77 | RAD52 (0.63) | MAPTRAD52KDM4EALDH1A1DRD2 | |
| Hydrochloric Acid SCHEMBL10858179 | 0.76 | MAPT (0.61) | MAPTRAD52KDM4EALDH1A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12596526-B2 | Computer-implemented method and a data processing hardware for processing sensor data points | AUMOVIO AUTONOMOUS MOBILITY GERMANY GMBH (DE) | 2026-04-07 | — | — | US | claimed |
| US-12472158-B2 | Methods of treating trigeminal nerve pain | VANDERBILT UNIVERSITY (US) | 2025-11-18 | — | — | US | claimed |
| EP-4378532-B1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | claimed |
| US-12461376-B2 | See-through type display apparatus and electronic device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-11-04 | — | — | US | claimed |
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-06-05 | — | — | US | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| EP-4125783-B1 | PIGMENT COMPRISING RAPHANUS SATIVUS EXTRACT AND MONTMORILLONITE | GIVAUDAN SA (CH) | 2025-04-30 | — | — | EP | claimed |
| CN-119227975-B | Method for analyzing close-to-ground space game situation based on improved intelligent pig game theory | 中国人民解放军军事航天部队航天工程大学 | 2025-03-04 | — | — | CN | claimed |
| CN-119485330-A | Efficient dynamic roadside unit deployment method and system capable of detecting witch attack | 西北工业大学 | 2025-02-18 | — | — | CN | claimed |
| CN-119310252-A | Comprehensive assessment method, device, equipment and medium for hypoxia condition | 自然资源部第二海洋研究所 | 2025-01-14 | — | — | CN | claimed |
| CN-101209014-A | Tobacco grafting breeding method | SHAOHUA LAN (CN) | 2008-07-02 | — | — | CN | claimed |
| WO-2008024495-A2 | BIOMARKERS ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2008-02-28 | — | — | WO | claimed |
| EP-1763954-A1 | DOMINANT COLOR EXTRACTION FOR AMBIENT LIGHT DERIVED FROM VIDEO CONTENT MAPPED THROUGH UNRENDERED COLOR SPACE | Koninklijke Philips Electronics N.V. (NL) | 2007-03-21 | — | — | EP | claimed |
| CN-1288924-C | Content charging and access control system for mobile network | FAR EASTONE TELECOMM CO LTD (CN) | 2006-12-06 | — | — | CN | claimed |
| WO-2006003602-A1 | DOMINANT COLOR EXTRACTION FOR AMBIENT LIGHT DERIVED FROM VIDEO CONTENT MAPPED THROUGH UNRENDERED COLOR SPACE | KONINKLIJKE PHILIPS ELECTRONICS N.V. (NL) | 2006-01-12 | — | — | WO | claimed |
| US-6005086-A | WHEREIN SAID POLYPEPTIDE IS A NUCLEAR RECEPTOR AND IS RESPONSIVE TO THE PRESENCE OF FARNESOID TO REGULATE THE TRANSCRIPTION OF ASSOCIATED GENE(S) | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1999-12-21 | — | — | US | claimed |
| EP-0941601-A1 | PROCESS FOR CALIBRATING A SCANNER | Heidelberger Druckmaschinen Aktiengesellschaft (DE) | 1999-09-15 | — | — | EP | claimed |
| WO-1998025400-A1 | PROCESS FOR CALIBRATING A SCANNER | HEIDELBERGER DRUCKMASCHINEN AG (DE) | 1998-06-11 | — | — | WO | claimed |
| EP-0609126-B1 | Semiconductor laser with two passive wavelength selectors | FRANCE TELECOM (FR) | 1997-03-26 | — | — | EP | claimed |
| EP-0251804-A1 | Wooden window frame having a weather-protecting shield on the outside and a vapour barrier on the inside | V. KANN RASMUSSEN INDUSTRI A/S (DK) | 1988-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD2 4882/4885DRD3 4873/4885ADRA2A 2285/4885 |
| US-12596526-B2 | Computer-implemented method and a data processing hardware for processing sensor data points | DDX41, DDX42, MDC1 | DRD2 545/4885DRD3 341/4885ADRA2A 4562/4885 |
| US-12472158-B2 | Methods of treating trigeminal nerve pain | NGF, ADRA2C, OPRL1 | DRD2 902/4885DRD3 1688/4885ADRA2A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.